Here are the results of our 'PAT' poll.
PharmTech Poll Results: How do you define ‘PAT,’ or ‘Process Analytical Technology’?
Thanks to all of you who participated in our poll! Here are a few of your answers, followed by the definition of ‘process analytical technology ’ given by FDA.
Your answers
1. “I believe that PAT is well-defined in their Guidance document in IV. PAT Framework, ‘a system for designing, analyzing, and controlling manufacturing ... with the goal of assuring final product quality. Analyzing is not just lab analysis but also includes statistical analysis of the data.’”
2. “PAT means incorporating analytical steps into each stage of the manufacturing process and using the results to evaluate and control the process in real time.”
According to FDA
FDA defines process analytical technology in its Guidance for Industry, as:
“Process Analytical Technology is: a system for designing, analyzing, and controlling manufacturing through timely measurements (i.e., during processing) of critical quality and performance attributes of raw and in-process materials and processes with the goal of ensuring final product quality.
“It is important to note that the term analytical in PAT is viewed broadly to include chemical, physical, microbiological, mathematical, and risk analysis conducted in an integrated manner.” The guidance is available here.
To add your definition, click here.
Click here to visit our poll archive.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.